

2007

The neuroendocrine impact of chronic stress on cancer

Premal H. Thaker
Washington University School of Medicine in St. Louis
Susan K. Lutgendorf
University of Iowa
Anil K. Sood
University of Texas M.D. Anderson Cancer Center

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Thaker, Premal H.; Lutgendorf, Susan K.; and Sood, Anil K., "The neuroendocrine impact of chronic stress on cancer." *Cell Cycle*. 6, 4. 430-433. (2007).
https://digitalcommons.wustl.edu/open_access_pubs/3030

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Perspective

The Neuroendocrine Impact of Chronic Stress on Cancer

Premal H. Thaker¹

Susan K. Lutgendorf²

Anil K. Sood^{3,4,*}

¹Division of Gynecologic Oncology; Department of Obstetrics and Gynecology; Washington University School of Medicine; St. Louis, Missouri USA

²Department of Psychology and Obstetrics and Gynecology; and the Holden Comprehensive Cancer Center; University of Iowa; Iowa City, Iowa USA

³Department of Gynecologic Oncology; and ⁴Department of Cancer Biology; University of Texas MD Anderson Cancer Center; Houston, Texas USA

*Correspondence to: Anil K. Sood; Departments of Gynecologic Oncology and Cancer Biology; University of Texas MD Anderson Cancer Center; 1155 Herman Pressler Unit 1362; PO Box 301439; Houston, Texas 77230 USA; Tel.: 713.745.5266; Fax: 713.792.7586; Email: asood@mdanderson.org

Original manuscript submitted: 12/28/06

Manuscript accepted: 01/09/07

Previously published online as a *Cell Cycle* E-publication:

<http://www.landesbioscience.com/journals/cc/abstract.php?id=3829>

KEY WORDS

angiogenesis, carcinoma, stress

ACKNOWLEDGEMENTS

This research was supported in part by U.S. NIH grants CA11079301 and CA10929801, The University of Texas MD Anderson Cancer Center Spore in Ovarian Cancer (2P50CA083639), and a Program Project Development Grant from the Ovarian Cancer Research Fund, Inc. to A.K.S., and NIH grant CA104825 to S.K.L.

ABSTRACT

Behavioral processes have long been suspected to influence many health processes including effects on cancer. However, mechanisms underlying these observations are not fully understood. Recent work has demonstrated that chronic behavioral stress results in higher levels of tissue catecholamines, greater tumor burden, and a more invasive pattern of ovarian cancer growth in an orthotopic mouse model. These effects are mediated primarily through the β_2 adrenergic receptor (ADRB2) activation of the tumor cell cyclic AMP (cAMP)-protein kinase A (PKA) signaling pathway. Additionally, tumors in stressed animals have increased vascularization and enhanced expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) -2 and -9. In this review, we highlight the importance of the neuroendocrine stress response in tumor biology and discuss mechanisms by which the β -adrenergic receptors on ovarian cancer cells enhance angiogenesis and tumor growth.

INTRODUCTION

Over twenty-five years ago, Engel recognized that biological factors alone cannot account for all changes in physical health and that social and behavioral dimensions must also be considered.¹ In clinical and epidemiological studies, cancer progression, and to a lesser extent, cancer onset have been related to chronic stress, depression, lack of social support and other psychological factors.²⁻⁶ Stress is a complex process encompassing environmental and psychosocial factors and initiates a cascade of information-processing pathways in both the central and peripheral nervous systems. Ultimately, the fight-or-flight stress responses in the autonomic nervous system (ANS) or the defeat/withdrawal responses in the hypothalamic-pituitary-adrenal axis (HPA) are generated and secrete catecholamines and cortisol, respectively (Fig. 1).^{7,8} Activation of these pathways in acute stress are necessary for survival and are adaptive processes. In contrast, chronic stress negatively affects most physiological systems due to prolonged exposure to catecholamines and glucocorticoids.⁹

Chronic stress has been shown to decrease cellular immune parameters, such as natural killer (NK) cell cytotoxicity and T-cell responses to mitogen stimulation.¹⁰⁻¹² Effects of biobehavioral factors on the immune system are thought to be mediated in part by the sympathetic nervous system, the HPA axis, and a variety of other hormones and peptides.^{13,14} To date, the majority of neuroendocrinological research dealing with stress and accelerated tumor growth has focused on suppressed immune response to malignant tissue.⁷ Recently, we and others have considered other biological pathways that may be affected by stress mediators. These observations are the focus of the current review.

NEUROENDOCRINE INFLUENCES ON CANCER

Tumorigenesis is a multistep process, and according to Hanahan and Weinberg, there are six essential acquired alterations in cell physiology that promote malignant growth: (1) self-sufficiency in growth signals, (2) insensitivity to anti-growth signals, (3) evasion of apoptosis, (4) limitless replicative potential, (5) sustained angiogenesis and (6) tissue invasion and metastasis.¹⁵ After a cell acquires tumorigenic potential, then cancer metastasis can occur if another series of sequential interrelated steps including proliferation/angiogenesis, invasion, embolism/circulation, transport, adherence in organs, adherence to vessel wall and extravasation occur.¹⁶ Tumor progression is a result of crosstalk between different cell types within the tumor and its surrounding supporting tissue, tumor stroma and micro-environment.¹⁷ Emerging research is now beginning to explore the role of neuropeptides




Figure 1. Key components of the central and peripheral stress systems. In response to neurosensory signals, the hypothalamus secretes corticotrophin-releasing factor (CRF) and arginine vasopressin (AVP), which cause the pituitary to secrete adrenocorticotrophic hormone (ACTH). Subsequently, ACTH promotes the production of glucocorticoids from the adrenal cortex. The sympathetic nervous system originates in the brain stem, and ultimately through post-ganglionic fibers releases noradrenaline. The adrenal medulla releases mainly adrenaline. Reprinted with permission from *Nature Reviews Cancer* (see ref. 8).

and neurotransmitters, which are increased in certain biobehavioral states on the multistep process of cancer metastasis.

In order to proliferate, tumor cells rely on nutrient and oxygen diffusion. The effects of stress-related hormones on tumor cell proliferation can be either stimulatory or inhibitory depending on the type of hormone and tumor type. For example, in breast carcinoma, activation of β -adrenergic receptors (ADRB) has been associated with accelerated tumor growth.¹⁸⁻²⁰ In contrast, catecholamines may inhibit tumor cell proliferation that may be mediated by α -adrenergic receptors or the dopamine transporter. Scarparo and colleagues found that melanoma cells treated with the α_1 -adrenergic agonist phenylephrine led to a dose-dependent decrease in proliferation, which could be reversed by the α_1 -adrenergic antagonist prazosin.²¹ Additionally, norepinephrine treatment shifted neuroblastoma cells expressing the dopamine transporter into the G_0/G_1 phase, thereby inhibiting proliferation.²² Similarly, the role of glucocorticoid hormones on proliferation is dual.^{23,24}

The ability of a tumor cell to invade and metastasize to distant tissues is highly dependent on malignant cell adhesion to the extracellular matrix.²⁵ Enserink and colleagues have shown that the β -agonist isoproterenol promotes ovarian cancer cell spreading and adhesion via integrins through Epac (exchange factor directly activated by cAMP)-Rap1 pathway.^{26,27} Additionally, there is growing evidence that stress hormones may affect tumor cell motility and invasion. Norepinephrine has been shown to induce breast and colon cancer migration.^{28,29} We have previously demonstrated that physiologic stress concentrations of norepinephrine and epineph-

rine can enhance the invasive potential of ovarian carcinoma cells via the ADRB-mediated increases in matrix metalloproteinases (MMPs). The β -adrenergic antagonist propranolol and pharmacologic blockade of MMPs abrogated the effects of norepinephrine on the increases in tumor cell invasive potential.³⁰ This work provided the in vitro evidence that stress hormones can increase the invasive potential of ovarian cancer cells.

Avoidance of apoptosis is a critical component of the metastatic cascade. Thus far, glucocorticoids, which regulate a variety of cellular processes, have been the focus of research elucidating the role of stress hormones on tumor cell survival. Glucocorticoids downregulate proapoptotic elements of the death receptor and mitochondrial apoptosis pathways in cervical and lung cancer cell lines.³¹ Wu and colleagues found that breast cancer cell lines pretreated with dexamethasone inhibited chemotherapy-induced apoptosis via transcriptional induction of serum and GC-inducible protein kinase-1 (SGK-1) and mitogen activated protein kinase phosphatase-1 (MKP-1).³² The antiapoptotic effects of glucocorticoid treatment could be reversed by blockade of SGK-1 and MKP-1.³² Additionally, glucocorticoids and catecholamines may act synergistically to facilitate cancer growth as evidenced in lung carcinoma cell lines.³³

Angiogenesis is a key process in the growth of most solid tumors beyond 1–2 mm in diameter, and their metastatic spread involves recruitment of nearby blood vessels to permeate the tumor.³⁴ In vascular endothelial cells, ischemic neoangiogenesis causes proliferation via overexpression of the ADRB.³⁵ Vascular endothelial growth factor (VEGF) is a key proangiogenic cytokine that is produced by tumor cells, endothelial cells, and platelets.³⁶ We have previously reported that higher levels of social support were correlated with lower VEGF levels in serum from presurgical patients with ovarian carcinoma providing a possible mechanism by which poor social support may be associated with disease progression.³⁷ We have also demonstrated that VEGF production by ovarian cancer cell lines was enhanced by stress hormones such as norepinephrine, epinephrine, and isoproterenol in vitro and blocked by the β -antagonist propranolol.³⁸ Based on our previous studies, we sought to elucidate whether chronic stress and the associated increase in sympathetic nervous system activity had a causal effect on growth and metastasis of ovarian cancer in vivo.³⁹

THE ROLE OF CHRONIC STRESS ON TUMOR GROWTH AND ANGIOGENESIS IN ORTHOTOPIC OVARIAN CARCINOMA

We recently demonstrated that chronic stress (daily restraint) quantitated by elevated organ catecholamine (norepinephrine and cortisol) levels enhanced the pathogenesis of ovarian carcinoma in vivo, as evidenced by increased tumor weight and more invasive pattern of metastasis including parenchymal liver, spleen, and diaphragm involvement. Propranolol, a non-specific β -blocker, completely blocked the effects of immobilization stress on tumor growth, indicating a critical role for β -adrenergic signaling in stress mediated increases in tumor growth. The β -adrenergic receptors are G-protein-coupled receptors that mainly function to transmit extracellular information to the interior of the cell, causing an activation of adenylyl cyclase and an accumulation of the second messenger cAMP to activate the protein kinase A pathway.⁴⁰ Ultimately, after catecholamine stimulation, the activation of the tumor cell cAMP-protein kinase A signaling pathway led to increased VEGF gene expression, resulting in increased tumor vascularization and more aggressive growth. A series of experiments using either ADRB-null cell lines,

pharmacological β -agonists, or ADRB-silencing with siRNA, demonstrated that ADRB2 on the tumor cells plays a functionally significant role in stress-mediated angiogenesis. The increased angiogenesis occurred in response to increases in catecholamine induced VEGF production by tumor cells. The tumor vasculature in stressed animals contained more tortuous and numerous blood vessels than controls, and was accompanied by a significant decrease in the proportion of blood vessels with pericyte coverage in tumors from stressed animals, which suggests more immature vasculature. Additionally, magnetic resonance imaging and kinetic analysis of the stressed tumors showed substantial anatomical and functional alterations in tumor vasculature.

Both propranolol and VEGF blocker such as the VEGF-R2 inhibitor PTK787 or the monoclonal VEGF-specific antibody bevacizumab completely blocked the stress induced effects on tumor burden and invasiveness. These results demonstrated that behavioral stressors can enhance the pathogenesis of ovarian carcinoma via

VEGF-mediated angiogenesis in vivo (Fig. 2), and underscores the importance of the neuroendocrine system in cancer pathogenesis.

CLINICAL OPPORTUNITIES AND CHALLENGES

The knowledge of how stress biology affects tumor initiation and pathogenesis is gradually expanding. Biobehavioral factors such as chronic stress, depression, and social support have been linked to tumor biology via their endocrine consequences and cell mediated immunity. Although the molecular pathways have not been fully elucidated, the studies to date indicate possible opportunities for behavioral and pharmacological intervention that target tumor-supporting neuroendocrine dynamics.

Pharmacologic and genetic manipulations identify β -adrenergic signaling as a central mediator of stress effects on cancer growth; therefore, pharmacological interventions such as β -blockers potentially could be used to alleviate the effects of stress on cancer growth and progression. Interestingly, in a large case-control study of prostate cancer patients, Perron and colleagues found that among individuals taking anti-hypertensive medications, only β -blockers were associated with a reduction in cancer risk.⁴¹ A cohort study of cardiovascular patients that used β -blockers had a 49% decrease in cancer risk compared to patients that never used β -blockers. Moreover, there was a 6% decrease in risk for every additional year of β -blocker use.⁴² However, other population-based case-control studies of breast carcinoma patients have not confirmed alterations in risk with the use of β -blockers.^{43,44} The efficacy of β -blockers in blocking the stress-mediated effects on tumor remains to be examined.

To the extent that behavioral and central nervous system processes modulate the activity of multiple hormones⁴⁵⁻⁴⁸ and those processes are linked to angiogenic parameters in human clinical studies^{37,49} interventions targeting neuroendocrine function at the CNS level might also represent novel strategies for protecting cancer patients from the detrimental effects of stress biology on the progression of malignant disease. Such interventions may include behavioral interventions alone or in combination with pharmacological approaches.⁸

CONCLUSIONS

Although research has shown that stress hormones affect tumor pathogenesis at multiple levels (initiation, tumor growth, and metastasis), our understanding of the underlying mechanisms is in its infancy and needs to be expanded. Based on the importance of the interplay between immunological and behavioral factors providing a favorable microenvironment for tumor initiation and growth, there is a crucial need to integrate a bio-behavioral perspective in therapeutic paradigms of human carcinoma. Interventions targeting neuroendocrine function at the level of the central nervous system could represent a novel strategy for protecting cancer patients from the deleterious effects of stress biology on cancer progression. Theoretically, these pharmacologic and behavioral interventions can be used concomitantly with conventional therapies to maximize efficacy and warrant further study, especially as cancer treatment evolves to encompass more patient-specific therapeutic approaches.

References

- Engel GL. The need for a new medical model: A challenge for biomedicine. *Science* 1977; 196:129-36.
- Stefanek M, McDonald PG. In: Miller SM, Bowen DJ, Croyle RT, Rowland J, eds. *Handbook of Behavioral Science and Cancer*. Washington DC: American Psychological Association. (In press).
- Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. *Lancet Oncol* 2004; 5:617-25.




Figure 2. Effects of stress on ovarian cancer growth via VEGF-mediated angiogenesis. Chronic stress leads to the activation of the autonomic nervous system (ANS) and the hypothalamic-pituitary-adrenal (HPA) axis, which result in release of catecholamines such as norepinephrine and epinephrine. These catecholamines then activate the β -adrenergic receptors on ovarian cancer cells to secrete VEGF and other angiogenic factors, leading to enhanced tumor growth and increased vascularity. Reprinted and modified with permission from *Nature Reviews Cancer* (see ref. 8).

4. Spiegel D, Giese-Davis J. **Depression and cancer: Mechanisms and disease progression.** *Biol Psychiatry* 2003; 54:269-82.
5. Price MA, Tennant CC, Smith RC, Butow PN, Kennedy SJ, Kossoff MB, Dunn SM. The role of psychosocial factors in the development of breast carcinoma: Part I. The cancer prone personality. *Cancer* 2001; 91:679-85.
6. Lillberg K, Verkasalo PK, Kaprio J, Helenius H, Koskenvuo M. Stressful life events and risk of breast cancer in 10,808 women: A cohort study. *Am J Epidemiol* 2003; 157:415-23.
7. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: Implications for health. *Nature Rev Immunol* 2005; 5:243-51.
8. Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK. The influence of bio-behavioural factors on tumour biology: Pathways and mechanisms. *Nature Rev Cancer* 2006; 6:240-8.
9. McEwen BS. Sex, stress and the hippocampus: Allostatic, allostatic load and the aging process. *Neurobiol Aging* 2002; 23:921-39.
10. Glaser R, MacCallum RC, Laskowski BF, Malarkey WB, Sheridan JF, Kiecolt-Glaser JK. Evidence for a shift in the Th-1 to Th-2 cytokine response associated with chronic stress and aging. *J Gerontol A Biol Sci Med Sci* 2001; 56:M477-82.
11. Ben-Eliyahu S, Page G. **In vivo assessment of natural killer cell activity in rats.** *Prog Neuroendocrine Immunol* 1992; 5:199-214.
12. Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM. Social support, psychological distress, and natural killer cell activity in ovarian cancer. *J Clin Oncol* 2005; 23:7105-13.
13. Ben-Eliyahu S, Yirmiya R, Liebeskind JC, Taylor AN, Gale RP. Stress increases metastatic spread of a mammary tumor in rats: Evidence for mediation by the immune system. *Brain Behav Immunity* 1991; 5:193-205.
14. Ben-Eliyahu S, Shakhar G, Page GG, Stefanski V, Shakhar K. Suppression of NK cell activity and of resistance of metastasis by stress: A role for adrenal catecholamines and β -adrenoceptors. *Neuroimmunomodulation* 2000; 8:154-64.
15. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000; 57-70.
16. Fidler IJ. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. *Nat Rev Cancer* 2003; 3:1-6.
17. Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. *Nat Rev Cancer* 2004; 4:839-49.
18. Badino GR, Novelli A, Girardi C, DiCarlo F. Evidence for functional β -adrenoceptor subtypes in CG-5 breast cancer cell. *Pharmacol Res* 1996; 33:255-60.
19. Vandewalle B, Evillion F, Lefebvre J. Functional β -adrenergic receptors in breast cancer cells. *J Cancer Res Clin Oncol* 1990; 116:303-6.
20. Marchetti B, Spinola PG, Pelletier G, Labrie F. **A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: Hormonal control of β -adrenergic receptors and correlation with tumor growth.** *J Ster Biochem Mol Biol* 1991; 38:307-20.
21. Scarpato AC, Sumida DH, Patrao MT, Avellar MC, Visconti MA, Maria de Lauro Castrucci A. **Catecholamine effects on human melanoma cells evoked by α 1-adrenoceptors.** *Arch Dermatol Res* 2004; 296:112-9.
22. Pifl C, Zezula J, Spittler A, Kattinger A, Reither H, Caron MG, Hornykiewicz O. Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. *Faseb J* 2001; 15:1607-1609.
23. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. *Nat Med* 2000; 6:703-6.
24. Simon WE, Albrecht M, Trams G, Dietel M, Holzel F. In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. *J Natl Cancer Inst* 1984; 73:313-21.
25. Boudreau N, Bissell MJ. Extracellular matrix signaling: Integration of form and function in normal and malignant cells. *Curr Opin Cell Biol* 1998; 10:640-6.
26. Rangarajan S, Enserink JM, Kuiperij HB, de Rooij J, Price LS, Schwede F, Bos JL. Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the β 2-adrenergic receptor. *J Cell Biol* 2003; 160:487-93.
27. Enserink JM, Price LS, Methi T, Mahic M, Sonnenberg A, Bos JL, Tasken K. The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the α 3 β 1 integrin but not the α 6 β 4 integrin. *J Biol Chem* 2004; 279:44889-96.
28. Drell IVth TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. **Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells.** *Breast Cancer Res Treat* 2003; 80:63-70.
29. Masur K, Niggemann B, Zanker KS, Entschladen F. **Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by β -blockers.** *Cancer Res* 2001; 61:2866-9.
30. Sood AK, Bhatti R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW. Stress hormone mediated invasion of ovarian cancer cells. *Clin Cancer Res* 2006; 12:369-75.
31. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM. **Glucorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.** *Cancer Res* 2003; 63:3112-20.
32. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. **Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells.** *Cancer Res* 2004; 64:1757-64.
33. Nakane T, Szentendrei T, Stern L, Virmani M, Seely J, Kunos G. **Effects of IL-1 and cortisol on β -adrenergic receptors, cell proliferation, and differentiation in cultured human A549 lung tumor cells.** *J Immunol* 1990; 145:260-6.
34. Folkman J. What is the evidence that tumors are angiogenesis dependent? *J Natl Cancer Inst* 1990; 82:4-6.
35. Iaccarino G, Ciccirelli M, Sorriento D, Galasso G, Campanile A, Santulli G, Cipolletta E, Cerullo V, Cimini V, Altobelli GG, Piscione F, Priante O, Pastore L, Chiariello M, Salvatore F, Koch WJ, Trimarco B. Ischemic neoangiogenesis enhanced by β 2-adrenergic receptor overexpression— a novel role for the endothelial adrenergic system. *Circulation Res* 2005; 97:1182-9.
36. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. *J Clin Oncol* 2002; 20:4368-80.
37. Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. *Cancer* 2002; 95:809-15.
38. Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M, Sood AK. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. *Clin Cancer Res* 2003; 9:4514-21.
39. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson J, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. *Nature Med* 2006; 12:939-44.
40. McDonald PH, Lefkowitz RJ. β -Arrestins: New roles in regulating heptahelical receptors' functions. *Cell Signal* 2001; 13:683-9.
41. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). *Cancer Causes Control* 2004; 15:535-41.
42. Algazi M, Plu-Bureau G, Flahault A, Dondon MG, Le MG. **Could treatments with β -blockers be associated with a reduction in cancer risk?** *Rev Epidemiol Sante Publique* 2004; 52:53-65.
43. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. *Cancer* 2003; 98:1504-13.
44. Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. *Arch Intern Med* 2000; 160:349-53.
45. Seeman TE, Berkman LF, Blazer D, Rowe JW. **Social ties and support and neuroendocrine function: The McArthur studies of successful aging.** *Ann Behav Med* 1994; 16:95-106.
46. Turner-Cobb J, Sephton S, Koopman C, Blake-Mortimer J, Spiegel D. Social support and salivary cortisol in women with metastatic breast cancer. *Psychosom Med* 2000; 62:337-45.
47. Antoni MH, Cruess DG, Cruess S, Lutgendorf S, Kumar M, Ironson G, Klimas N, Fletcher MA, Schneiderman N. Cognitive behavioral stress management intervention effects on anxiety, 24-hour urinary norepinephrine output, and T-cytotoxic/suppressor cells over time among symptomatic HIV-infected gay men. *J Consult Clin Psychol* 2000; 66:31-45.
48. Antoni MH, Cruess S, Cruess DG, Kumar M, Lutgendorf S, Ironson G, Dettmer E, Williams J, Klimas N, Fletcher MA, Schneiderman N. Cognitive-behavioral stress management reduces distress and 24-hour urinary free cortisol output among symptomatic HIV-infected gay men. *Ann Behav Med* 2000; 22:29-37.
49. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. *Cancer* 2005; 104:305-13.